Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers
Authors:
- Angela ChanACAngela Chan
- Nancy NixonNNNancy Nixon
- Muna Al-KhaifiMuna Al-Khaifi
- Alain BestavrosABAlain Bestavros
- Christine BlythCBChristine Blyth
- Winson Y. CheungWCWinson Y. Cheung
- Caroline HammCHCaroline Hamm
- Thomas Joly-MischlichTJThomas Joly-Mischlich
- Mita MannaMita Manna
- Tom McFarlaneTMTom McFarlane
- Laura V. MinardLMLaura V. Minard
- Sarah NaujokaitisSNSarah Naujokaitis
Open Access
- 14 July 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 402
Abstract
The adjuvant treatment landscape for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer (EBC) is rapidly evolving, with a diverse range of therapeutic options—including endocrine therapies, bisphosphonates, ovarian function suppression, olaparib, CDK4/6 inhibitors, and emerging agents such as immunotherapy. While these advances have markedly improved patient outcomes, they also introduce challenges related to implementation, monitoring, and resource allocation. Notably, therapies like CDK4/6 inhibitors require particularly close monitoring, creating logistical and capacity challenges for medical oncologists, whose workloads are already stretched due to rising cancer incidence and treatment complexities. These challenges underscore the need for innovative care delivery solutions to ensure patients with EBC continue to receive optimal care. This paper offers a comprehensive guide—a playbook—of multidisciplinary-team-based care models designed to optimize adjuvant treatment delivery in EBC. Drawing on real-world evidence and successful applications across Canadian centers, we explore models led by nurses, nurse practitioners (NPs), general practitioners in oncology (GPO), and pharmacists. Each model leverages the unique expertise of its team to manage treatment toxicities, facilitate adherence, and enhance patient education, thereby promoting effective and sustainable care delivery. Importantly, these models are not intended to compete with one another, but rather to serve as a flexible recipe book from which breast cancer care teams can draw strategies tailored to their local resources and patient needs. By detailing implementation strategies, benefits, and challenges—in many instances supported by quantitative metrics and economic evaluations—this work aims to inspire care teams nationwide to optimize the adjuvant management of patients with HR+, HER2– EBC.Keywords
Funding Information
- Novartis Pharmaceuticals Canada Inc.
This publication has 85 references indexed in Scilit:
- Electronic patient-reported outcomes as digital therapeutics for patients with cancer: a narrative review of current practices and future directionsInternational Journal of Clinical Oncology, 2024
- 245P Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysisAnnals of Oncology, 2024
- Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclibAnnals of Oncology, 2022
- Effectiveness and implementation of models of cancer survivorship care: an overview of systematic reviewsJournal of Cancer Survivorship, 2021
- A nurse practitioner–led model of care improves access, early assessment and integration of oncology services: an evaluation studySupportive Care in Cancer, 2020
- Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung CancerJAMA, 2019
- Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinibSupportive Care in Cancer, 2018
- Nurse-led versus doctor-led care for bronchiectasisCochrane Database of Systematic Reviews, 2018
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United StatesJAMA, 2015